{"nctId":"NCT00662532","briefTitle":"Antibiotic Study for Dental Implants","startDateStruct":{"date":"2008-04"},"conditions":["Periodontitis"],"count":44,"armGroups":[{"label":"Minocycline HCl","type":"EXPERIMENTAL","interventionNames":["Drug: Minocycline HCl"]},{"label":"No Intervention","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Minocycline HCl","otherNames":["antibiotic"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 21 years of age and good general health\n* appropriately documented Informed Consent\n* willing to adhere to the study schedule, prohibitions and restrictions specified in the protocol\n* female subjects must meet the pregnancy and contraceptive requirements\n* must have oral health appropriate for study inclusion\n\nExclusion Criteria:\n\n* oral health inappropriate for study inclusion\n* females self-reporting pregnancy or lactation, or having a positive urine pregnancy result\n* reporting any of the following conditions:\n* allergy to a tetracycline-class drug\n* systemic medical conditions requiring antibiotic prophylaxis prior to invasive dental procedures\n* active systemic infectious disease such as hepatitis, human immunodeficiency virus (HIV) or tuberculosis\n* diagnosed with clinically significant or unstable organic disease, or compromised healing potential, heart murmurs, histories of rheumatic fever, valvular disease or prosthetic joint replacement\n* participation in a dental clinical trial or use of an investigational drug within 30 days of enrollment\n* employees of the Investigator or study center, with direct involvement in the proposed study or other studies, as well as family members of the employees or the Investigator\n* anyone who the investigator determines should not be included in the study for any reason that could compromise safety or the analysis of study results","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall PD Reduction","description":"Mean reduction of probing depth (PD) of qualified implant sites is derived by calculating the change of PD per qualified implant site (PD at baseline minus PD at post-baseline), and then averaging the site-specific PD changes per subject","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.63"},{"groupId":"OG001","value":"0.66","spread":"0.63"}]}]}]},{"type":"SECONDARY","title":"Initial PD Reduction","description":"Mean reduction of probing depth (PD) of qualified implant sites is derived by calculating the change of PD per qualified implant site (PD at baseline minus PD at post-baseline), and then averaging the site-specific PD changes per subject","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"0.63"},{"groupId":"OG001","value":"0.49","spread":"0.58"}]}]}]},{"type":"SECONDARY","title":"BOP Percent Reduction From Baseline","description":"Bleeding on Probing (BOP) percentage is calculated as the number of implant sites with bleeding divided by the number of implant sites per subject times 100% at each visit; reduction of BOP percentage is the BOP percentage at baseline minus the BOP percentage post-baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.17","spread":"38.27"},{"groupId":"OG001","value":"22.53","spread":"31.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.75","spread":"32.19"},{"groupId":"OG001","value":"32.86","spread":"41.35"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":22},"commonTop":["Tooth Abscess","Gastrooesophageal Reflux Disease","Bite","Ear Infection","Infection"]}}}